Benchmarking tocilizumab use for giant cell arteritis.
作者信息
Conway Richard, Putman Michael S, Mackie Sarah L
机构信息
Department of Rheumatology, St. James's Hospital.
Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
出版信息
Rheumatol Adv Pract. 2022 May 9;6(2):rkac037. doi: 10.1093/rap/rkac037. eCollection 2022.
Abstract
摘要
相似文献
1
Benchmarking tocilizumab use for giant cell arteritis.托珠单抗治疗巨细胞动脉炎的基准研究。
Rheumatol Adv Pract. 2022 May 9;6(2):rkac037. doi: 10.1093/rap/rkac037. eCollection 2022.
2
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.托珠单抗诱导和维持巨细胞动脉炎缓解的疗效：一项 2 期、随机、双盲、安慰剂对照试验。
Lancet. 2016 May 7;387(10031):1921-7. doi: 10.1016/S0140-6736(16)00560-2. Epub 2016 Mar 4.
3
Tocilizumab in Giant Cell Arteritis.托珠单抗治疗巨细胞动脉炎
Cardiol Rev. 2018 Nov/Dec;26(6):321-330. doi: 10.1097/CRD.0000000000000204.
4
Tocilizumab for relapsing and remitting giant cell arteritis: a case series.托珠单抗治疗复发缓解型巨细胞动脉炎：病例系列研究。
J Med Case Rep. 2022 Oct 27;16(1):389. doi: 10.1186/s13256-022-03625-y.
5
[Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients].托珠单抗在巨细胞动脉炎和主动脉炎中节省皮质类固醇的疗效及耐受性：尼姆大学医院关于11例患者的经验
Rev Med Interne. 2018 Feb;39(2):78-83. doi: 10.1016/j.revmed.2017.11.001. Epub 2017 Dec 6.
6
Tocilizumab in the treatment of giant cell arteritis.托珠单抗治疗巨细胞动脉炎。
Immunotherapy. 2018 Mar 1;10(6):465-472. doi: 10.2217/imt-2017-0182. Epub 2018 Mar 5.
7
[Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review].托珠单抗治疗巨细胞动脉炎的临床及生物学疗效：3例病例报告及文献综述
Rev Med Interne. 2014 Jan;35(1):56-9. doi: 10.1016/j.revmed.2012.12.012. Epub 2013 Sep 26.
8
Trial of Tocilizumab in Giant-Cell Arteritis.托珠单抗治疗巨细胞动脉炎的临床试验。
N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849.
9
Stevens Johnson Syndrome in a Patient with Giant Cell Arteritis During Short Term Tocilizumab Therapy.短期托珠单抗治疗巨细胞动脉炎患者时发生的史蒂文斯-约翰逊综合征
Cureus. 2020 Apr 13;12(4):e7662. doi: 10.7759/cureus.7662.
10
Tocilizumab for giant cell arteritis with corticosteroid-resistant progressive anterior ischemic optic neuropathy.托珠单抗治疗糖皮质激素抵抗性巨细胞动脉炎伴进展性前部缺血性视神经病变。
Joint Bone Spine. 2017 Oct;84(5):615-619. doi: 10.1016/j.jbspin.2017.04.009. Epub 2017 May 9.
引用本文的文献
1
Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives.从免疫学和临床角度评估白细胞介素-6通路抑制在胃肠道白塞病中的作用
Biomedicines. 2025 Jan 20;13(1):247. doi: 10.3390/biomedicines13010247.
2
Advances and challenges in management of large vessel vasculitis.大血管血管炎管理的进展与挑战
Rheumatol Immunol Res. 2023 Dec 19;4(4):188-195. doi: 10.2478/rir-2023-0028. eCollection 2023 Dec.
3
Giant cell arteritis: reviewing the advancing diagnostics and management.巨细胞动脉炎：探索先进的诊断与管理。
Eye (Lond). 2023 Aug;37(12):2365-2373. doi: 10.1038/s41433-023-02433-y. Epub 2023 Feb 14.
4
Metabolic bone health considerations in giant cell arteritis and polymyalgia rheumatica.巨细胞动脉炎和风湿性多肌痛的代谢性骨骼健康问题。
Womens Health (Lond). 2023 Jan-Dec;19:17455057221147385. doi: 10.1177/17455057221147385.
5
Comment on: Benchmarking tocilizumab use for giant cell arteritis.关于“托珠单抗治疗巨细胞动脉炎的基准评估”的评论
Rheumatol Adv Pract. 2022 Aug 23;6(3):rkac069. doi: 10.1093/rap/rkac069. eCollection 2022.
本文引用的文献
1
Tocilizumab for the treatment of giant cell arteritis in Scotland: a report on behalf of the Scottish Society for Rheumatology standards subgroup.托珠单抗治疗苏格兰巨细胞动脉炎：代表苏格兰风湿病学会标准小组的报告
Rheumatol Adv Pract. 2022 Mar 9;6(1):rkac017. doi: 10.1093/rap/rkac017. eCollection 2022.
2
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.2021 年美国风湿病学会/脉管炎基金会巨细胞动脉炎和 Takayasu 动脉炎管理指南。
Arthritis Rheumatol. 2021 Aug;73(8):1349-1365. doi: 10.1002/art.41774. Epub 2021 Jul 8.
3
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.2018 年版 EULAR 大血管血管炎管理建议更新。
Ann Rheum Dis. 2020 Jan;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672. Epub 2019 Jul 3.
4
Trial of Tocilizumab in Giant-Cell Arteritis.托珠单抗治疗巨细胞动脉炎的临床试验。
N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849.
5
Cognitive biases associated with medical decisions: a systematic review.与医疗决策相关的认知偏差：一项系统综述。
BMC Med Inform Decis Mak. 2016 Nov 3;16(1):138. doi: 10.1186/s12911-016-0377-1.
6
Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents.日本医院类风湿关节炎的治疗模式及生物制剂起始治疗的预测因素。
Curr Med Res Opin. 2017 Jan;33(1):101-107. doi: 10.1080/03007995.2016.1239191. Epub 2016 Oct 3.
7
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.应用多准则决策分析方法建立糖皮质激素毒性指数（GTI）。
Ann Rheum Dis. 2017 Mar;76(3):543-546. doi: 10.1136/annrheumdis-2016-210002. Epub 2016 Jul 29.
8
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.成人起病的类风湿关节炎和其他炎性自身免疫性风湿性疾病的终生风险。
Arthritis Rheum. 2011 Mar;63(3):633-9. doi: 10.1002/art.30155.
Zotero 插件